Your browser doesn't support javascript.
loading
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
Benito, Juliana; Ramirez, Marc S; Millward, Niki Zacharias; Velez, Juliana; Harutyunyan, Karine G; Lu, Hongbo; Shi, Yue-Xi; Matre, Polina; Jacamo, Rodrigo; Ma, Helen; Konoplev, Sergej; McQueen, Teresa; Volgin, Andrei; Protopopova, Marina; Mu, Hong; Lee, Jaehyuk; Bhattacharya, Pratip K; Marszalek, Joseph R; Davis, R Eric; Bankson, James A; Cortes, Jorge E; Hart, Charles P; Andreeff, Michael; Konopleva, Marina.
Afiliación
  • Benito J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ramirez MS; Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Millward NZ; Department of Experimental Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Velez J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Harutyunyan KG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lu H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shi YX; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Matre P; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jacamo R; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ma H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konoplev S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • McQueen T; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Volgin A; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Protopopova M; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mu H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lee J; Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bhattacharya PK; Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Marszalek JR; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Davis RE; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bankson JA; Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortes JE; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hart CP; Threshold Pharmaceuticals, Inc., South San Francisco, California.
  • Andreeff M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas. mkonople@mdanderson.org.
Clin Cancer Res ; 22(7): 1687-98, 2016 Apr 01.
Article en En | MEDLINE | ID: mdl-26603259
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Mostazas de Fosforamida / Médula Ósea / Profármacos / Leucemia / Microambiente Tumoral / Hipoxia / Antineoplásicos / Nitroimidazoles Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Mostazas de Fosforamida / Médula Ósea / Profármacos / Leucemia / Microambiente Tumoral / Hipoxia / Antineoplásicos / Nitroimidazoles Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article